Tirzepatide is a synthetic dual agonist of the glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors. It has been the subject of extensive research for its effects on glucose regulation, insulin sensitivity, and body weight modulation. By activating both GIP and GLP-1 pathways, Tirzepatide may offer synergistic benefits in metabolic studies compared to single-pathway agonists.

Preclinical and clinical models have explored its potential in managing type 2 diabetes, obesity, and cardiometabolic dysfunction. Ongoing studies also investigate its influence on lipid metabolism, appetite suppression, and energy expenditure.

For research use only. Not for human or veterinary use.

Products are provided in lyophilized powder form and require reconstitution prior to use in research or laboratory testing.